Best Medical Writing Specialists Oslo Near Me

4worldlovers: LINK Medical is a full-service Nordic CRO providing product development services for the pharmaceutical and medical device industries across Northern Europe. Our Scandinavian roots and culture provide a high-quality service delivery based on respect, work integrity and a strong focus on solutions. We are a pragmatic problem-solver, empowering our experienced specialists with modern technology that will change your expectations of a CRO partner. Our promise is to improve and accelerate your product development through transformative methods, active communication and optimal solutions.

We offer a strategic partnership, providing you with highly competent teams and evidence-based documentation that drive superior clinical outcomes. Reaching from early phase development to post-marketing, we provide expert guidance through every stage of product development – all from ONE source. You can rely on smooth service delivery through the LINK Advantage, a unique leveraging of our in-house expertise to deliver the right competencies where and when you need them. With a well-integrated local presence in the Nordics, UK, and Germany, you can trust us to make your journey to market as simple and cost-effective as possible.

"The TPP workshop provided by LINK Medical substantially improved our strategy and made the planning of clinical trials much easier"

"The TPP workshop gave us an excellent, clear understanding of the regulatory pathway. Having experts from different areas of the health care sector in the same room, answering all our questions, was a fantastic benefit for us"

The health economic model proved to be an extremely useful tool, enabling Mentis Cura to explore the monetary effect of implementing it's product in multiple scenarios.

4worldlovers:
Project management | Regulatory affairs | Monitoring| Data management | Biostatistics | Pharmacovigilance | Medical writing


The Smerud Medical Research Group (SMERUD) is a leading, commercial clinical Contract Research Organisation (CRO) providing full-service clinical trial services to biotech, pharma, med-tech and academic sponsors. We primarily operate in Northern Europe with headquarters in Norway and subsidiary offices in Denmark, Finland, Sweden, United Kingdom, Germany, Austria and Poland. Thus, our clients will benefit from our local presence and point of contact and also full access to our firm’s overall expertise and experience.


The company is owned by a ‘family office’, and this guarantees ownership involvement, orientated towards long-term perspectives and leveraging of the client-provider relationship, including a personalized approach. We are passionate about clinical trials and consider the development of a study protocol or a study report as nothing less complex and beautiful than art, aiming for perfection in the final document. We are very proud of our highly competent and well educated staff, most of whom could claim seniority in the business of drug development.


We look at professional pride as a key value and our promise to clients and employees is that we will always adhere to premium business ethics and aim to deliver first class quality in all our services. Being innovators and entrepreneurs in several areas, we remain committed to our corporate vision: ‘Semper excelsior’.

The company was founded back in May 1993, meaning that we have provided high-level services and generated value in a high number of assets through profitable operations, covering all significant therapeutic areas for 30 years in a highly competitive and changing market. Through the many decades of operations, we have learned that whatever we do, it has to be among the best on a world scene. Rather than aiming for a huger size (‘been there, done that’), our philosophy remains loyal to what it was some 30 years ago: never compromise on quality, and maintain a never-say-die attitude. Our mission is to plan, conduct, analyse and report all of our projects – big or small – with the same approach and attention to delivery of high-quality services and product development.

We provide all services needed to conduct a clinical trial, including clinical project management, feasibility analyses, clinical study protocol writing, clinical trial applications (CTIS and NRAS), clinical operations incl. monitoring and site management, biostatistics and data management, pharmacovigilance, medical monitoring and writing of the clinical study report and publications arising from the study. Our Regulatory Affairs unit offers general regulatory affairs services, regulatory intelligence and strategy, scientific advice meetings, orphan drug designation applications and a limited clinical supplies services. Further, we offer legal representation, training, QA and GCP auditing services.

Being a relatively small company with some 35-40 headcounts, we primarily focus on our niche expertise areas:

Clinical trials in the Northern Europe (the Nordic Area + the UK, Germany and Poland)

Planning, conduct, analysis and reporting of clinical trials, primarily in phase I and II

Management of full clinical development of orphan drugs, including regulatory strategy and consultations

Our experience and size, makes us and ideal provider to biotech companies sponsoring early clinical stage trials, fulfilling one of our slogans ‘Big enough to manage, small enough to care’.

SMERUD is providing senior clinical development expertise to the market. The majority of our clients in the consulting market are small-to-medium sized enterprises, typically with very strong drug discovery, laboratory and/or pre-clinical modelling experience, but with relatively scarce experience from clinical development. In most cases, the client would present to SMERUD their current overall idea about their target indication and target market. SMERUD’s consulting unit would then typically be assigned to establish ‘the optimal clinical development strategy’, materialized through a detailed, integrated Clinical Development Plan (CDP). The CDP would include the desired Target Product Profile (TPP) and a detailed description of all activities to be completed in order to attain the attributes defined in the TPP, and with associated crude budgets. The timing of all activities including deferral of non-critical activities until completion of clinical proof-of-concept would be outlined.

The CDP/TPP would form the basis for regulatory dialogue (incl. formal Scientific Advice Meetings) with the Competent Authorities, for consultation with global, regional and national Key Opinion Leaders, and for early business development activities with potential (big pharma) industry partners. It is our experience that a thorough CDP will be a valuable complement to the Business Plan, when start-up companies or other SMEs are pitching their concept and offer to potential investors, whether smaller family offices in the earlier financing stage or more professional investors and VC alike, in later stages.